Amarin announces senior management changes

Connecticut firm appoints ceo, president and principal accountant

Amarin Corporation, a US clinical-stage biopharmaceutical company with a focus on cardiovascular disease, has appointed Joseph Zakrzewski as chief executive. He will continue to serve as chairman of the board.

Zakrzewski has more than 20 years of experience, including holding the position of chief operating officer of Reliant Pharmaceuticals when Omacor/Lovaza was developed and acquired in 2007 by GlaxoSmithKline. He was most recently chief executive of Xcellerex, a Massachusetts-based biotechnology company. Although he currently serves on the boards of directors and in other advisory roles for various companies, Amarin is his primary business commitment.

Additionally, John Thero has been promoted to Amarin’s president. Since November 2009, he has been the company’s chief financial officer.

Prior to joining Amarin, Thero was chief financial officer at ViaCell, where he helped guide the sale of the company, and Abiomed, during its transition from a development-stage company into a commercial entity.

Colin Stewart, who was Amarin’s president and ceo, resigned last month to address personal matters.

In connection with these changes, Frederick Ahlholm, vice president finance, has become the company’s principal accounting officer.

You may also like

Manufacturing

Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025

The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Pharmaceutical

Moderna named a top employer by Science for eleventh consecutive year

Moderna was recognised for its commitment to continuous innovation and a culture that reflects the values of its employees.
Pharmaceutical

Pharma leaders to join together to shape the future of the industry at CPHI Frankfurt Leadership Summit

As the pharmaceutical industry enters a defining period of transformation, Informa Markets is hosting an exclusive Leadership Summit at this year’s CPHI Frankfurt, bringing together some of the sector’s most influential executives to address the challenges and opportunities shaping global healthcare
Pharmaceutical

Takeda and Innovent Biologics partner to advance next-gen oncology medicines

Takeda will establish manufacturing of two next-generation late-stage investigational medicines in the US and will receive exclusive commercialisation rights for IBI363 and IBI343 outside the US and China
Manufacturing

Roquette opens pharmaceutical innovation centre in Brazil

The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development

Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia

AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026
Subscribe now